[
Effective January 1, 2017, Independence will update its list of
specialty drugs that require member cost-sharing
(e.g., copayment, deductible, and coinsurance). Cost-sharing applies to select
medical benefit specialty drugs for
members who are enrolled in Commercial FLEX products and other select plans.
The member?s cost-sharing amount
is based on the terms of the member?s benefit contract. Individual benefits
should be verified.
The updated list will include approximately 130 drugs, including new
additions for Cinqair® (reslizumab), InflectraTM
(infliximab)*, Nucala® (mepolizumab), and
Probuphine® (buprenorphine).
The updated list is available on our website. The current 2016 cost-sharing list
can be accessed through this link until December 31, 2016.
* For members enrolled in Commercial FLEX products,
cost-sharing applies to all biosimilars of infliximab approved by the U.S. Food
and
Drug Administration.
]